GlassScriptPhysician profile
Danny M Chachere
NPI 1982994448
$17,461.12
in general payments reported to CMS, 2019-2025
66 companies · $2,558 in 2025
The $2,558 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,398 · 2020: $2,116 · 2021: $2,868 · 2022: $2,450 · 2023: $1,984 · 2024: $2,087 · 2025: $2,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,629.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,711.47 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biogen, INC. | $1,628.21 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $1,208.79 | 2020-2025 | Xcopri |
| Abbvie INC. | $1,072.02 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $952.16 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $900.35 | 2019-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $729.41 | 2019-2025 | |
| Lilly USA, LLC | $721.29 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $621.61 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Abbott Laboratories | $612.90 | 2019-2025 | Infinity |
| Csl Behring | $535.84 | 2019-2025 | Hizentra |
| Emd Serono, INC. | $479.85 | 2019-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $391.89 | 2019-2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $361.17 | 2019-2025 | Crexont |
| Sunovion Pharmaceuticals INC. | $285.44 | 2019-2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Chachere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.